Procter & Gamble is acquiring the consumer health products division of German conglomerate Merck KGaA for $4.2 billion, its first major deal since activist investor Nelson Peltz won a seat on the company's board of directors. This adds to P&G's lineup of health products like Crest, Pepto-Bismol and Vicks.

Why it matters: P&G's buyout of Merck KGaA's consumer health business comes right after Novartis sold its own to GlaxoSmithKline. Meanwhile, Pfizer is still looking to unload its bigger over-the-counter division to a market that now excludes two large purchasers.

The bottom line: "Morgan Stanley analyst Vincent Meunier said the price implied a valuation of 4.7x sales and around 19x EBITDA for the business, at the high end of recent deals in the sector." — Ludwig Burger, Reuters